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BestBETs for Vets
Supporting veterinary clinicians in making
evidence-based decisions
Nutraceuticals versus carprofen in dogs with
osteoarthritis
Clinical Scenario
Sally White is a 12 year female neutered black Labrador presented to you with right forelimb lameness and
difficulty jumping into the car. She has decreased range of movement in both hips and the right elbow. You
have just x-rayed her hips, stifles, shoulders and elbows and she has significant osteoarthritis in all joints. You
recommend a course of Rimadyl (carprofen) but Mrs White, Sally’s owner, takes daily glucosamine for her
osteoarthritis and wants to know if it works in dogs. She is also very worried about the side effects of NSAIDs.
You wonder if a nutraceutical could be better at controlling the clinical signs of osteoarthritis than carprofen...
3-Part Question (PICO)
In [dogs with osteoarthritis] is a [glucosamine & chondroitin supplement vs. carprofen] better at [reducing the
clinical signs of osteoarthritis]?
Search Strategy
MEDLINE(R) In-Process & Other Non-Indexed Citations and MEDLINE(R) 1946 to
Present using the OVID interface
(dog.mp. OR dogs.mp. OR canine.mp. OR canines.mp. OR canis.mp. OR canid.mp. OR canids.mp. OR
canidae.mp. OR exp Dogs/ OR exp Canidae/)
AND
(osteoarthritis.mp. OR osteo-arthritis.mp. OR arthritis.mp. OR joint disease.mp. OR joint diseases.mp. OR
DJD.mp. OR exp Osteoarthritis/ OR exp Arthritis/ OR exp Joint Diseases/)
AND
(carprofen.mp. OR rimadyl.mp. OR rimifin.mp. OR canidryl.mp. OR carprodyl F.mp. OR dolagis.mp. OR
rycarfa.mp. OR zenecarp.mp. OR carprogesic.mp.)
AND
(glucosamine.mp. OR glucosamines.mp. OR chondroitin.mp. OR chondroitins.mp. OR nutraceutical.mp. OR
nutraceuticals.mp. OR exp Glucosamine/ OR exp Chondroitin sulfates/ OR exp Chondroitin/ OR exp
Chondroitin Sulfate Proteoglycans/ OR exp Dietary Supplements/)
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CAB Abstracts 1910 to Present using the OVID interface
(dog.mp. OR dogs.mp. OR canine.mp. OR canines.mp. OR canis.mp. OR canid.mp. OR canids.mp. OR
canidae.mp. OR exp dogs/ OR exp Canis/ OR exp Canidae/)
AND
(osteoarthritis.mp. OR osteo-arthritis.mp. OR arthritis.mp. OR joint disease.mp. OR joint diseases.mp. OR
DJD.mp. OR exp osteoarthritis/ OR exp arthritis/ OR exp joint diseases/)
AND
(carprofen.mp. OR rimadyl.mp. OR rimifin.mp. OR canidryl.mp. OR carprodyl F.mp. OR dolagis.mp. OR
rycarfa.mp. OR zenecarp.mp. OR carprogesic.mp.)
AND
(glucosamine.mp. OR glucosamines.mp. OR chondroitin.mp. OR chondroitins.mp. OR nutraceutical.mp. OR
nutraceuticals.mp. OR exp glucosamine/ OR exp chondroitin sulfate/)
Search Outcome
MEDLINE
13 papers found in MEDLINE search
10 papers excluded as they don't meet the PICO question
0 papers excluded as they are in a foreign language
0 papers excluded as they are review articles/in vitro research/conference proceedings
3 total relevant papers from MEDLINE
CAB Abstracts
16 papers found in CAB search
13 papers excluded as they don't meet the PICO question
0 papers excluded as they are in a foreign language
0 papers excluded as they are review articles/in vitro research/conference proceedings
3 total relevant papers from CAB
Total relevant papers
3 relevant papers from both MEDLINE and CAB Abstracts
Summary of Evidence
Alves et al.(2017) Portugal
Title:
Effect of an oral joint supplement when compared to carprofen in
the management of hip osteoarthritis in working dogs
Patient
group:
15 working police dogs from the Guarda Nacional Republica
Study
Type:
Randomised controlled trial
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Outcomes:
Canine Brief Pain Inventory (CBPI) - split into Pain Severity Score (PSS) and Pain
Interference Score (PIS) completed by trainers at baseline, 15 days, 30 days, then
monthly to 6 months.
Hudson Visual Analog Scale (HVAS) completed by trainers at baseline, 15 days, 30
days, then monthly to 6 months.
Qualitative quality of life assessment completed by trainers at baseline, 15 days, 30
days, then monthly to 6 months (mentioned in the results section). 
Haematology and biochemical data and urinalysis performed at days 0, 30 and 70. 
Key Results:
No significant difference found between baseline data and any subsequent time point using the
CBPI (no difference in either PSS or PIS), HVAS or quality of life measures for either the
glucosamine/chondroitin supplement or the positive control (carprofen) groups. 
No significant changes in haematological, biochemical or urinary parameters reported in either
group. 
The authors report on "treatment success" for individual dogs receiving carprofen; no individual
dogs' treatment success was described for dogs receiving glucosamine/chondroitin.
Study Weaknesses:
Poor reporting of basic data (e.g. age, breed, sex and living conditions of dogs not described).
Small sample size of 15 dogs not justified with a power calculation.
No data provided to determine whether groups were comparable at baseline. 
Method of randomisation not reported.
Veterinary surgeons performing clinical assessments may not have been blinded. 
CBPI and HVAS tools not adequately described within this paper to enable disease severity data to
be interpreted. 
Quality of life assessment measure used was not validated.
Haematological and biochemical data not reported. 
Only aggregated results were provided; unclear how many dogs were assessed at each timepoint.
Results of statistical analysis not presented in numerical format. 
Relatively large spread of scores for CBPI and HVAS at all timepoints
No statement on who funded the study.
Attachment:
Evidence appraisal (/soe_attachments/521/3914-CA Alves paper.pdf)
McCarthy et al. (2007) Ireland
Title:
Randomised double-blind, positive-controlled trial to assess the efficacy of
glucosamine/chondroitin sulfate for the treatment of dogs with osteoarthritis.
Patient
group:
42 client owned dogs with osteoarthritis recruited via veterinarians
Study
Type:
Controlled clinical trial
Outcomes:
Severity of clinical signs (clinical scoring system) – made up of 5 parts - lameness,
joint mobility, pain on palpation, weight-bearing, overall score of clinical condition. 
Measured at day 14, 42, 70, and 98
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Key Results:
Glucosamine/chondroitin group – significant improvements (P<0.001) in pain, weight bearing and
overall condition at Day 70 compared to pre-treatment scores. No significant improvement for these
outcomes was seen at any other time points, and no significant effect was identified on joint
mobility or lameness at any time point. 
Carprofen group – significant improvements in all five outcomes, but not at all time points.  Weight
bearing and joint mobility were improved at 14, 42 and 70 days (also at day 98 for weight bearing).
Joint pain was improved at day 42, lameness at day 70 and overall score at days 42 and 70.
The average improvement in pain scores at day 70 were comparable between groups.
A mean reduction in disease score in the carprofen group was greater than the
glucosamine/chondroitin group group at day 70 for lameness, joint mobility, weight bearing and
overall condition.
Study Weaknesses:
Patients were not randomly selected
Patients were assigned to alternate treatment groups via order or recruitment rather than true
randomisation
Outcome measure used was unvalidated and possibly subjective
Sample size justification was not given although a power calculation was performed
Groups may not have been comparable by age or weight
Unclear how scoring was performed on dogs with both hip and elbow osteoarthritis
Basic data were poorly described
Seven dogs dropped out before day 70
The authors discuss non-inferiority but this trial does not appear to have been designed to test non-
inferiority
Conclusions were made about glucosamine/chondroitin even though no comparisons to a placebo
were available
Study funded by manufacturers of the supplement
Attachment:
Evidence appraisal (/soe_attachments/521/3915-CA McCarthy final.pdf)
Moreau et al. (2003) Canada
Title:
Clinical evaluation of a nutraceutical, carprofen and meloxicam for the treatment of dogs
with osteoarthritis.
Patient
group:
71 dogs with clinically and radiologically confirmed osteoarthritis recruited from veterinary
teaching hospital records or via a newspaper advertisement
Study
Type:
Randomised controlled trial
Outcomes:
Changes in ground reaction forces (GRF) compared to healthy dogs
Subjective owner assessment of the dog's activity and pain
Subjective veterinary assessment
Radiographic assessment
Wide range of haematological and biochemical parameters assessed 
Faecal samples tested for occult blood
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Bottom line
Key Results:
The authors report that dogs treated with chondroitin-glucosamine-manganese showed no
significant response in objective gait analysis (GRF) or both of the subjective assessments but no
data are presented to support this. 
There was a significant improvement in the subjective orthopaedic assessment of dogs treated with
carprofen at day 30 (summary data only presented), but no significant response in terms of the
owners’ subjective assessment (no data presented).
Some dogs treated with carprofen showed improvements in GRF, but none of the dogs returned to
"normal" values. 
Study Weaknesses:
Patients were not randomly selected
The subjective scoring systems used by owners and veterinary surgeons were not validated
Details of how the subjective scoring system was used by veterinary surgeons are not clearly
described
There was no description of assessor blinding for owners or veterinary surgeons in the materials
and methods section
Results are poorly presented and some results described in the text have no supporting data
Sample size justification was not given and a power calculation was not performed
Multiple dogs were excluded from the analyses
Conclusions are drawn on animals treated and completing the study rather than intention to treat
Multiple subgroups are described, the statistical validity of which is unclear
GRF data are compared with results from "10 normal dogs" about which no detail is provided
Results comparing the efficacy of carprofen and glucosamine/chondroitin are reported only in a one
line summary
The study was funded by Boehringer Ingelheim, manufacturers of Metacam which was the third
comparator treatment included in this study
Attachment:
Evidence appraisal (/soe_attachments/521/3916-CA Moreau final.pdf)
Comments
This is an updated version of the BET originally published in September 2013, authored by Dr Martin Downes
and Dr Rachel Dean, with the addition of a new paper.
The quality of the three studies included in this BestBET are questionable. All three lack a sample size
calculation, and data on how randomisation was performed was not always provided, or clear. One of the
trials (Moreau et al., 2003) made no comparison between the two treatments under investigation even though
they set out to do this in their aim.
There is a critically appraised topic published by McKenzie (2010) reviewing the same topic, which drew
similar conclusions to this BestBET.  Systematic reviews (Aragon et al., 2007, Sanderson et al., 2009) have
appraised the evidence associated with a range of treatments for osteoarthritis, but these reviews did not
specifically examine the difference between carprofen and glucosamine/chondroitin sulphate in relation to
efficacy. Further good quality studies are needed to gain more scientific knowledge on this subject area.
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There are a lack of good quality clinical trials to answer this
question. There is a suggestion that carprofen is superior to
glucosamine/chondroitin supplements in reducing clinical signs of
osteoarthritis but better quality evidence is required to definitively
answer the question. 
Disclaimer
The BETs on this website are a summary of the evidence found on a topic and are not clinical
guidelines. It is the responsibility of the individual veterinary surgeon to ensure appropriate decisions
are made based on the specific circumstances of patients under their care, taking into account other
factors such as local licensing regulations. Read small print (/disclaimer)
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